List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

  1. Clinical Development of a Therapeutic Agent for COPD

    SBC: BIOMARCK PHARMACEUTICALS, LTD            Topic: NHLBI

    DESCRIPTION provided by applicant Hypersecretion of mucus into the respiratory airways is a major contributing factor in several lung diseases including chronic pulmonary disease COPD asthma cystic fibrosis allergic rhinitis and bronchiectasis Despite the obvious medical importance there presently are no effective therapies to control excess mucus secretion in these diseases and very ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Improved diagnostic and monitoring assays for thyroid cancer

    SBC: Soymeds Inc            Topic: NCI

    DESCRIPTION provided by applicant Thyroid cancer is the most common type of endocrine malignancy New thyroid cancers patients are identified daily and most patients live for decades following diagnosis Thyroglobulin TG levels in the sera or in fine needle biopsies of thyroid cancer patients are routinely quantified using various agency approved e g FDA immunoassays for diagnostic and p ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Manufacturing Processes for Tissue Engineered Vascular Grafts

    SBC: HUMACYTE, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant This Phase IIB SBIR application is responsive to NHLBI RFA HL andquot NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart Lung Blood and Sleep Disorders and Diseases R andquot This RFA solicits work on andquot basic applied and clinical research on all product and service development related to the ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Long-Acting G-CSF Analog for Treating ARS

    SBC: Bolder Biotechnology, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. MINDFULNESS BASED SUBSTANCE ABUSE PREVENTION PROGRAM FOR ADOLESCENTS WITH FASD

    SBC: Innovation Research And Training, Inc.            Topic: NICHD

    Adolescents with Fetal Alcohol Spectrum Disorder FASD are at risk for substance use and abuse Given the dearth of interventions designed specifically for adolescents with FASD there exists a need for evidence based preventive intervention programs for this population Thus the goal of the proposed Phase II application is to complete the product development and evaluate the effectiveness of t ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government